To print: Select File and then Print from your browser's menu

Title: New Formulation of Allergan's Alphagan P Receives U.S. FDA Approval

"New Formulation of Allergan's Alphagan P Receives U.S. FDA Approval"

IRVINE, CA -- August 19, 2005 -- Allergan, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market Alphagan® P (brimonidine tartrate ophthalmic solution) 0.1%, indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The new product is an optimized formulation of Alphagan (brimonidine tartrate ophthalmic solution) 0.2%, and was developed to further minimize drug exposure while maintaining the drug's favorable efficacy profile. This FDA approval is the latest advance in the Alphagan Franchise, which includes Alphagan P 0.15%, and currently reflects the third-largest selling glaucoma franchise in the world(1). "Our goal in developing Alphagan P 0.1% has been to ensure maximal efficacy of brimonidine with the least drug exposure possible," said Dr. Scott Whitcup, Allergan's Executive Vice President, Research & Development. "By improving bioavailability compared to the original Alphagan 0.2%, we have managed to decrease drug concentration by half without sacrificing efficacy. This milestone underscores Allergan's commitment to providing eye care specialists and patients with safe and efficacious medicines." In a clinical trial, Alphagan P ophthalmic solution 0.1% was proven to have IOP-lowering efficacy equivalent to Alphagan 0.2%, effectively lowering IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2-6 mmHg. Alphagan P 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. The most frequently reported adverse events included allergic conjunctivitis, conjunctival hyperemia and eye pruritus. SOURCE: Allergan, Inc.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.